Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

216 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-14

Study Completion Date

2019-03-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chemotherapy induced peripheral neuropathy (CIPN) is one of the most deleterious adverse effect of neurotoxic anticancer drugs affecting up to 40% of patients. These neurotoxic anticancer agents include mainly: cisplatin (bronchopulmonary cancers), oxaliplatin (colorectal cancers), paclitaxel (breast cancers and bronchopulmonary cancers), docetaxel (breast cancers and bronchopulmonary cancers) and bortezomib (multiple myeloma).

CIPN affects not only the quality of life of patients, it also has a major impact on oncology strategy, forcing oncologists to reduce dose-intensity, to stop an ongoing chemotherapy regimen and to change therapeutic strategies, with a risk of compromising patients' survival.

There is no real preventive or curative treatment (except duloxetine) for CIPN and it is not known what is the practice of oncologists in France? However, it is essential to know the degree of sensitivity of oncologists to this problem and their practice.

With this study, the investigators propose to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy

NCT03514680

Cancer Chemotherapy-induced Peripheral Neuropathy

COMPLETED NA

Chemotherapy Induced Peripheral Neuropathy (CIPN)

NCT03272919

Chemotherapy-induced Peripheral Neuropathy

COMPLETED NA

Assessing Functional Impairments in Patients With Chemotherapy-Induced Peripheral Neuropathy

NCT07315334

Chemotherapy Induced Peripheral Neuropathy (CIPN)

NOT_YET_RECRUITING

Chemotherapy Induced Neuropathy in Cancer Patients

NCT06491082

Chemotherapy-induced Peripheral Neuropathy

RECRUITING

Vincristine-induced Peripheral Neuropathy in Adult Survivors of Childhood and Adolescent Leukemia

NCT05759052

Chemotherapy-induced Peripheral Neuropathy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This observational and cross-sectional study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).

French oncologist will be contacted by email thanks to the regional cancer networks. Answer to the survey will be done online.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapy-induced Peripheral Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oncologists

French oncologists

survey

Intervention Type OTHER

to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

survey

to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.

Intervention Type OTHER